Gastrointestinal stromal tumour (GIST) is the most frequent sarcoma of the gastrointestinal tract with an age-adjusted incidence of ∼6.8 new cases per million per year ([@bib30]). However, the true incidence of GIST may be higher as incidental GISTs are relatively frequent ([@bib2]; [@bib24]). Gastrointestinal stromal tumour is most commonly found in the stomach (60--70%), followed by the small intestine (20--30%), colon, and rectum, and it is infrequent in the oesophagus and mesentery ([@bib20]). The most common locations for metastases are the liver and the peritoneum ([@bib25]). Gastrointestinal stromal tumour occurs predominantly in the middle-aged and older population, with a median age at diagnosis of ∼60 years ([@bib22]). Developmentally, GIST cells likely arise from pluripotent precursor mesenchymal cells that normally differentiate into the interstitial cells of Cajal and play a key role in the regulation of gut motility. Activating mutations in the *KIT* gene are found in 70 to 80% of primary GISTs, and mutations in the platelet-derived growth factor alpha (*PDGFRA*) are present in further 10 to 15% of the tumours. These mutations are considered to be early and driving oncogenic events in most GISTs ([@bib9]).

Imatinib mesylate is a selective inhibitor of KIT, PDGFR*α*/*β* and BCR-ABL kinases, and was the first Food and Drug Administration-approved tyrosine kinase inhibitor (TKI) for the treatment of GIST. Imatinib is now the standard first-line treatment for advanced GIST. At present, several other TKIs are either approved or under investigation for the treatment of imatinib-resistant GIST ([@bib5]). The responsiveness of GIST to imatinib differs with the type and location of *KIT* or *PDGFRA* mutations. Patients with GIST with *KIT* exon 11 mutation generally achieve a longer progression-free survival (PFS) than those with *KIT* exon 9 mutation ([@bib11]). Approximately 15% of patients with GIST progress on imatinib within the first 3 months on therapy (primary resistance) if GIST genotype is not used for patient selection ([@bib15]), and further 40 to 50% develop resistance within 2 years of therapy initiation (secondary resistance) ([@bib32]). Acquired imatinib resistance often coincides with the appearance of second *KIT* mutations encoding for a protein resistant to imatinib ([@bib3]).

When GIST progresses on imatinib or when the patient does not tolerate imatinib, the standard second-line treatment is sunitinib ([@bib34]). The median PFS was 5.1 months on second-line sunitinib in a randomised trial ([@bib13]) with a tendency for better PFS in patients with *KIT* exon 9 mutation compared with other genotypes ([@bib27]). However, patients eventually progress on sunitinib. Regorafenib was approved in 2013 for the third-line treatment of patients with GIST who no longer respond to imatinib and sunitinib based on a randomised phase 3 study ([@bib12]). However, sunitinib and regorafenib are usually less well tolerated than imatinib, and may cause hand-foot syndrome, fatigue, and hypertension that may sometimes be severe, and responses to sunitinib and regorafenib may remain short. A few TKIs have been evaluated as the third-line or later line treatment post therapy with imatinib and sunitinib including nilotinib ([@bib8]), pazopanib ([@bib14]), and sorafenib ([@bib23]) (reviewed in [@bib5]).

Dovitinib is a multikinase inhibitor of the vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, fibroblast growth factor receptor-1 (FGFR-1), FGFR-2, FGFR-3, PDGFR*β*, KIT, colony-stimulating factor 1 receptor, Fms-like tyrosine kinase 3, and PDGFR*α* ([@bib31]; [@bib28]). In a phase 1 study, dovitinib administration to a patient with GIST resulted in disease control for 8 months when both imatinib and sorafenib had failed ([@bib29]). Based on the kinase inhibition spectrum and the anecdotal clinical evidence, we initiated this phase 2, multicentre, open-label, single-arm, nonrandomised study to assess the antitumour activity and safety of dovitinib in patients with GIST refractory or intolerant to imatinib in the second-line setting.

Materials and methods
=====================

Patients
--------

Patients ⩾18 years of age with histologically confirmed GIST that was either unresectable and/or metastatic with documented disease progression while on therapy with imatinib were eligible. Patients with surgically removed localised GIST that recurred on adjuvant imatinib or within the first 3 months after discontinuation of adjuvant imatinib were also eligible, as well as patients with unresectable and/or metastatic GIST who were intolerant to imatinib. Patients were required to have ⩾1 measurable GIST lesion at baseline and Eastern Cooperative Oncology Group performance status ⩽2. The tumours were required to be KIT-positive in immunostaining, or when KIT-negative, to stain positively for discovered on GIST-1 (DOG-1, anoctamin); patients with a tumour histologically compatible with GIST and a mutation of *KIT* or *PDGFRA* were also eligible regardless of the result of immunostaining for KIT and DOG-1. Exclusion criteria included the use of cytotoxic drugs ⩽4 weeks before initiation on dovitinib, major surgery ⩽4 weeks before starting dovitinib, history of pulmonary embolism, or untreated deep venous thrombosis within the past 6 months. Patients with impaired cardiac function, brain metastasis, or the long QT syndrome were excluded.

The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each participating centre. Written informed consent was obtained from the patients before study entry. The study was conducted according to the ethical principles of the Declaration of Helsinki.

Study design
------------

The primary objective was to assess the efficacy of dovitinib in terms of the disease control rate (DCR; complete response+partial response (PR)+stable disease (SD)), at 12 weeks on study. The secondary objectives included assessment of PFS, time to treatment failure, the duration of response and SD, time to progression (TTP), overall response rate (ORR), overall survival (OS), DCR at the end of treatment, and safety and tolerability of dovitinib. The exploratory objectives were to evaluate tumour response using the Choi criteria and to correlate response with DCR and PFS, and to assess the associations between *KIT* and *PDGFRA* mutations and tumour response and cancer progression. This study (DOVIGIST) is an exploratory, phase 2, multicentre, open-label, single-arm, nonrandomised trial.

Study drug administration
-------------------------

Dovitinib was administered orally (500 mg day^−1^, 5 days on/2 days off), and was taken either with or without food. One treatment cycle was considered to last for 28 days. Dovitinib treatment was continued until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment on patient request.

Study assessments
-----------------

### Efficacy and safety assessments

Tumour assessment and response to dovitinib therapy were evaluated according to the Response Evaluation Criteria In Solid Tumours (RECIST v1.1) and the Choi criteria. Tumour responses were assessed by local radiological review. All known sites of tumour lesions were investigated using computerised tomography or magnetic resonance imaging at baseline within 21 days before initiating therapy, on day 28 of the cycle 1, then every 8 weeks until 24 weeks on study, and subsequently every 12 weeks thereafter until disease progression. Whenever disease progression was suspected, additional imaging was carried out. Physical examination, blood cell counts, blood biochemistry, and urine analysis were carried out at baseline, on day 1 and 15 of the first cycle, and then on day 1 of each cycle.

### Assessment of the primary objective

The primary objective was DCR, defined as the proportion of patients with the best overall response of CR, PR, or SD at week 12 on study. Best overall response was assessed by the investigators according to RECIST v1.1, and it was rederived both at 12 weeks and at the end of therapy, as SD ⩾6 weeks based on investigator assessment could not be confirmed in two patients. Besides the rederived assessment, the best overall response as assessed by the investigators is also provided for comparison.

The best overall response of complete response corresponded with at least two determinations of CR, at least 4 weeks apart before progression. Partial response corresponded with at least two determinations of PR or better at least 4 weeks apart but not qualifying for CR. Stable disease is defined as at least one SD assessment \>6 weeks after the start of treatment. The best overall response was progressive disease, when disease progressed ⩽6 weeks after the start of treatment.

Patients with a best overall response assessed as 'unknown' were not regarded as responders, but were included in the denominator for the calculation of DCR. 'Unknown' was defined according to the modified RECIST criteria, that is, cases not qualifying for confirmed CR or PR and who did not have SD after more than 6 weeks or early progression within the first 6 weeks.

### Safety assessments

Safety was monitored throughout the study according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4. The side effects were graded at the scheduled visits.

### Patient follow-up

All patients were followed up for 28 days after the last dose of dovitinib for safety assessments. In addition, patients discontinuing dovitinib for reasons other than death, disease progression, lost to follow-up, or withdrawal of consent continued to have tumour assessments done every 3 months until radiological progression, start of new therapy for GIST, or until 2 years had elapsed from the study entry.

Statistical considerations
--------------------------

The highest DCR at week 12 that would indicate the treatment with dovitinib to be clearly ineffective (*p*~0~) was defined as 20%, as this would be below the proportion of patients who had a clinical benefit by week 22 (month 5) after treatment with sunitinib ([@bib13]), whereas *p*~1~ was the minimum required DCR to show effectiveness, chosen to be 45%. A minimum of 29 evaluable patients were required to be enrolled to test the null hypothesis H~0~ that *p*⩽*p*~*0*~ against the alternative hypothesis H~1~ that *p*⩾*p*~1~.

Analyses of primary and secondary variables were carried out using the full analysis set. Exact confidence intervals (CIs) were computed according to Clopper--Pearson using a one-sided level of significance of 5% (two-sided *α* of 10%).

Results
=======

Patients
--------

A total of 39 patients were enrolled in the study between January 2012 and July 2014 from 14 centres located in Europe and were included in the safety analyses. Of these, 38 patients had histologically confirmed GIST and were included in the efficacy analyses.

The median age of the 38 patients with histologically verified GIST at the time of study entry was 60 years (range, 32--77 years). Three (7.9%) patients progressed on adjuvant imatinib, 3 within 3 months after discontinuation of adjuvant imatinib, 27 (71.1%) had disease progression on imatinib administered for advanced GIST, and 8 (21.1%) patients were intolerant to imatinib (3 patients had both progressed on imatinib and were also intolerant to imatinib). Patient demographics and baseline characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The median time period since initial GIST diagnosis to the first dose of dovitinib was 46.3 months (range, 3.5--135 months).

Efficacy
--------

All 38 patients completed the study; the most common primary reasons for dovitinib discontinuation were disease progression (in 27 patients (71.1%)) and adverse events (in 8 patients (21.1%)). Four patients underwent surgical resection of metastases after study entry; of these, three patients had incomplete resection and one patient had macroscopically complete resection. These patients were not censored from the analysis.

At week 12, 20 patients (52.6%, 90% CI, 38.2--66.7) had the disease controlled (had a PR or SD) based on the rederived best overall response criteria. One patient (2.6%) had a PR as the best overall response, and 19 patients (50.0%) had SD ([Table 2](#tbl2){ref-type="table"}). Therefore, the DOVIGIST study met its primary preset efficacy end point (DCR\>20%). The best overall response was classified as unknown in 13 patients (34.2%) (8 patients with documented tumour progression after 6 weeks of treatment without confirmation of whether SD lasted ⩾6 weeks, 1 patient stopped treatment early due to a protocol deviation, and 4 patients exited the study early due to adverse events). Based on the investigator assessment, the DCR at 12 weeks was 55.3% (21 of 38; 90% CI, 40.7--69.1) ([Table 2](#tbl2){ref-type="table"}). The best percentage change from the baseline in the sum of the lesion diameters and the RECIST overall response at the end of study are shown in [Figure 1](#fig1){ref-type="fig"}.

By the analysis cutoff date (31 July 2014), 30 PFS events (due to progression) were observed, and the median PFS was 4.6 months (90% CI, 2.8--7.4 months) ([Figure 2](#fig2){ref-type="fig"}). Eight patients (21.1%) discontinued the study due to adverse events and were censored on the date of dovitinib discontinuation. The estimated probability of a patient being progression free at week 12 was 67.5%. The overall survival of the patient population is presented in [Figure 3](#fig3){ref-type="fig"}.

The ORR (CR+PR) was 2.6% (1 of 38; 90% CI, 0.1--11.9) and 5.3% (*n*=2; 90% CI, 0.9--15.7%) at week 12 and at the end of study, respectively (based both on rederived and investigator assessment). The median TTP was 4.0 months (95% CI, 2.7--7.3). The proportion of patients with SD for up to 6 months was 52% (13 of 25 patients), and the median duration of SD was 167 days (range, 57--490 days). The median OS was not reached, as a majority of the patients were censored because of starting of a new antineoplastic therapy. A sensitivity analysis without censoring at the start of new anticancer therapy showed comparable results.

### Exploratory efficacy based on the Choi criteria

The DCR at week 12 and end of study in the full-analysis set were 73.7% (28 of 38 patients; 90% CI, 59.5--85.0). The overall DCR at week 12 was 44.7% (17 patients; 90% CI, 30.9--59.3) and at end of study was 47.4% (18 patients; 90% CI, 33.3--61.8).

### Response by *KIT* and *PDGFRA* mutation

Eight of 14 patients with *KIT* exon 11 mutation and 1 of 5 patients with *KIT* exon 9 mutation had SD as the best overall response at week 12. All three patients with *PDGFRA* mutation had SD.

Safety
------

The mean daily dose of dovitinib was 437.8 mg, and the median relative dose intensity was 96.2% (range, 49.1--102.2). The median duration of exposure of dovitinib was 14.4 weeks (range, 3.6--105.1 weeks), and 24 patients (61.5%) had an exposure lasting \>12 weeks.

All 39 patients used concomitant medications during the treatment with dovitinib. Twenty-three patients (59.0%) required dose adjustment/interruption and eight patients (20.5%) discontinued therapy, regardless of the study drug relationship. Dose interruption was required in 26 (66.7%) of 39 patients, with adverse effects being the reason for dose interruption in 18 patients (69.2%). The reason for dose interruption in the remaining eight patients included a dosing and dispensing error and laboratory test abnormalities.

No significant association in intolerance to imatinib and dovitinib was noted. Of the 8 patients intolerant to imatinib, 4 (50.0%) had no dose reduction on dovitinib as compared with 17 (54.8%) out of the 31 patients who tolerated imatinib (*P*=0.807, *χ*^2^ test); the mean number of dovitinib dose reductions per patient were 1.7 (s.d., 2.4) and 1.3 (0.5), respectively.

Thirty-seven of 39 patients (94.8%) had an adverse effect reported, and 17 (43.6%) and 8 (20.5%) patients, respectively, had grade 3 or grade 4 adverse effects ([Table 3](#tbl3){ref-type="table"}). The most frequently observed grade 3 adverse effects were hypertension (7 patients, 17.9%), fatigue (5 patients, 12.8%), vomiting, hypertriglyceridaemia, and *γ*-glutamyl transferase increase (4 patients each, 10.3%). Most of these adverse effects were suspected to be dovitinib related. Almost all patients (36 patients, 92.3%) experienced ⩾1 adverse effects suspected to be study drug related, a majority of which were grade 3 or 4 (23 patients, 59%). Grade 3 adverse effects occurred in 19 patients (48.7%); the most frequent ones (occurred in ⩾3% of the patients) were fatigue (5 patients, 12.8%), hypertension (4 patients, 10.3%), diarrhoea, *γ*-glutamyl transferase increase, vomiting, hypertriglyceridaemia (3 patients each, 7.7%), nausea, anaemia, neutropenia, mucosal inflammation, and asthenia (2 patients each, 5.1%). Grade 4 adverse effects suspected to be related to dovitinib were observed in four patients (10.3%). The grade 4 adverse effects recorded were leukopaenia, pancytopenia, cardiac arrest, cholestasis, and *γ*-glutamyl transaminase increase (1 patient each, 2.6%).

Serious adverse effects suspected to be study treatment related were reported in 10 patients (25.6%); these were fatigue (2 patients, 5.1%), vomiting (2 patients, 5.1%), anaemia, leukopaenia, pancytopenia, cardiac arrest, tachycardia, diarrhoea, nausea, cholestasis, tracheobronchitis, decreased weight, decreased appetite, peripheral neuropathy, pulmonary embolism, toxic skin eruption, and aortic thrombosis (1 patient each, 2.6%). One patient died during the study due to a cardiac arrest, which was suspected to be related to dovitinib.

Discussion
==========

In this phase 2 study, we investigated the safety and efficacy of dovitinib administered at 500 mg day^−1^, 5 days on/2 days off in patients with imatinib refractory/intolerant GIST, but who had not been treated with sunitinib or regorafenib. This study met its prespecified efficacy objective demonstrating a DCR (CR+PR+SD) of 52.6% at 12 weeks. The median PFS was 4.6 months, and the median OS was not reached.

The identification of driver mutations in genes encoding receptor tyrosine kinases and development of potent inhibitors of these kinases revolutionised treatment for GIST. Imatinib was approved in 2002 for the treatment of patients with metastatic and/or unresectable GIST and is the standard therapeutic option in the first-line setting ([@bib10]). Tyrosine kinase inhibitor therapies have greatly improved survival of patients with advanced GIST. According to one estimate, the median survival of patients with unresectable or metastatic GIST increased after the introduction of imatinib from 12 to 33 months ([@bib4]). A more recent study suggests that the median survival of patients with advanced GIST treated with TKIs increased from 1 to at least 5 years ([@bib7]). However, GIST patients frequently develop resistance to imatinib and have disease progression mainly due to secondary *KIT* mutations ([@bib3]; [@bib16]; [@bib33]; [@bib15]), and therefore, there is still an unmet medical need. Most of the acquired mutations occur in *KIT* exon 13, exon 14 (encode the adenosine triphosphate/drug-binding pocket), or exon 17 that encodes the kinase activation loop ([@bib33]; [@bib15]). The median time to progression on first-line imatinib is about 3 years, although some patients remain progression free for longer than 10 years.

Sunitinib, an approved second-line treatment for imatinib refractory/intolerant GIST ([@bib34]), has potent activity on GISTs with *KIT* exon 13 and 14 mutations that confer imatinib resistance, but relatively little activity against *KIT* exon 17 and exon 18 mutations ([@bib17]; [@bib26]; [@bib18]). In a phase 2 study on patients (*n*=97) intolerant/progressing on imatinib, sunitinib demonstrated a clinical benefit rate (PR or SD \>6 months) of 58% and 34% for patients with *KIT* exon 9 or exon 11 mutations, respectively. The median PFS (19.4 *vs* 5.1 months) and OS (26.9 *vs* 12.3 months) were better for patients with primary *KIT* exon 9 mutations than patients with exon 11 mutations ([@bib17]). In addition, PFS and OS were longer in patients with secondary *KIT* exon 13 and 14 mutations compared with those with mutations in exons 17 and 18 ([@bib17]). In the present study, 8 (57%) of 14 patients with *KIT* exon 11 primary tumour mutation had the disease controlled at least for 6 weeks, but the small numbers preclude from making firm conclusions about the efficacy of dovitinib in different mutational subsets.

Dovitinib had been evaluated earlier in the treatment of advanced GIST in the third-line setting ([@bib21]). In that study with 30 patients whose GIST had progressed at least on imatinib and sunitinib, a median PFS of 3.6 months and median OS of 9.7 months were achieved, and the DCR was 13% at 24 weeks after study entry. One patient achieved PR and other 21 patients achieved SD, whereas 6 patients had PD ([@bib21]).

Besides sunitinib and dovitinib, a few other TKIs have been investigated as second-line therapy for imatinib-resistant GIST. These include vatalanib ([@bib19]), motesanib ([@bib6]), and masitinib ([@bib1]). Vatalanib, an inhibitor of KIT, PDGFRA, and the VEGFRs, was found well tolerated. Two of 26 patients (8%) treated with prior imatinib only for advanced GIST achieved PR and further 12 patients (66%) had stable disease lasting for at least 6 months, and the median time to progression was 5.8 months ([@bib19]). Of the 102 patients with imatinib-resistant GIST and treated with motesanib, another inhibitor of KIT, PDGFRA, and the VEGFRs, 3 (3%) patients achieved PR, 60 (59%) had SD for ⩾8 weeks, 14 (14%) had durable SD lasting for a minimum of 24 weeks, and the median progression-free survival was 3.7 months ([@bib6]). Masitinib, an inhibitor of KIT, PDGFR, and the fibroblast growth factor receptor-3, was compared with sunitinib in a small randomised trial in the second-line setting in patients whose GIST had progressed on imatinib. The median progression-free survival was 3.7 months in the masitinib arm, which was similar to that of patients treated with sunitinib. Masitinib was, however, better tolerated than sunitinib ([@bib1]). Taken together, the response rate and the median time to progression observed in the present study with dovitinib might not differ substantially from those obtained with these other TKIs, including sunitinib, in the second-line setting, although efficacy comparisons between different studies are notoriously difficult and might even be misleading.

The side-effect profile of dovitinib was comparable with TKIs that inhibit the VEGFRs besides KIT and PDGFRA, with hypertension frequently detected. One patient died from cardiac arrhythmia, which may have been due to dovitinib-related hypertension or other cardiac toxicity. Dovitinib was associated with relatively frequent gastrointestinal tract toxicity including nausea, vomiting, and diarrhoea. Dovitinib treatment was discontinued owing to adverse events in 8 (21%) patients, and the dosing was either reduced or interrupted in 22 (58%) patients owing to toxicity. Overall, these findings suggest that the tolerability of dovitinib might be roughly similar to other TKIs that inhibit multiple kinases including KIT, PDGFRA, and the VEGFRs.

The study has limitations. The response to dovitinib was unknown in a considerable number of patients (13 patients, 34%). This was due to interpreting responses and SD conservatively. Patients with a best overall response classified as 'unknown' were not regarded as responders, but were included in the denominator for the calculation of the DCR. Patients not qualifying for confirmed CR or PR and who did not have SD after more than 6 weeks or early progression within the first 6 weeks after study entry were considered to have 'unknown' response. We also calculated the proportion of patients who had the disease controlled in two ways, as SD on investigator assessment could not be confirmed in two cases. This did not, however, substantially alter the study primary outcome ([Table 2](#tbl2){ref-type="table"}). Finally, we lacked mutation analysis results of *KIT* and *PDGFRA* in 34% of the patients.

In sum, dovitinib was associated with a clinically meaningful benefit as second-line treatment of patients with imatinib-refractory GIST or who did not tolerate imatinib, and the primary efficacy end point of the study was met. Dovitinib safety profile was generally acceptable, but one patient was judged to have died from dovitinib-related cardiac arrhythmia. Many of the patients with primary tumour *KIT* exon 11 mutation benefitted from dovitinib, and further studies might identify a specific subgroup of patients who benefit from dovitinib therapy in the second-line setting. While sunitinib remains the standard second-line treatment, the results of the present study suggest a need for further investigation of dovitinib in the treatment of advanced GIST.
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###### Baseline demographics and GIST characteristics

  **Variable**                                                       **Total,** ***N*****=38**
  ------------------------------------------------------------------ ---------------------------
  Median age, years                                                  60.0 (32--77)
  Male, *n* (%)                                                      22 (57.9)
  Race, *n* (%)                                                       
   Caucasian                                                         29 (76.3)
   Other                                                             9 (23.7)
  ECOG performance status, *n* (%)                                    
   0                                                                 23 (60.5)
   1                                                                 15 (39.5)
  Primary site of cancer, *n* (%)                                     
   Oesophagus                                                        1 (2.6)
   Stomach                                                           15 (39.5)
   Small intestine                                                   15 (39.5)
   Rectum                                                            2 (5.3)
   Other                                                             5 (13.2)
  Tumour histology, *n* (%)                                           
   Epithelioid                                                       5 (13.2)
   Spindle                                                           17 (44.7)
   Mixed                                                             11 (28.9)
   Other                                                             5 (13.2)
  Mitotic count per 50 HPFs, *n* (%)                                  
   ⩽5/50                                                             8 (21.1)
   \>5/50 to ⩽10/50                                                  6 (15.8)
   \>10/50                                                           10 (26.3)
   Not evaluable[a](#t1-fn2){ref-type="fn"}                          9 (23.7)
   Missing                                                           5 (13.2)
  Metastatic site, *n* (%)[b](#t1-fn3){ref-type="fn"}                 
   Pleural effusion (malignant)                                      1 (2.6)
   Lung                                                              1 (2.6)
   Thoracic lymph nodes                                              2 (5.3)
   Spleen                                                            1 (2.6)
   Liver                                                             26 (68.4)
   Stomach                                                           1 (2.6)
   Peritoneum                                                        17 (44.7)
   Adrenal                                                           1 (2.6)
   Bladder                                                           2 (5.3)
   Bone, lumbar vertebrae                                            1 (2.6)
   Other                                                             6 (15.8)
  Median number of target lesions (range)                            2 (1--5)
  Median longest diameter of the largest target lesion, cm (range)   7.0 (1.3--25.0)
  Disease progression while on imatinib, *n* (%)                     33 (86.8)
  Median time on imatinib, days (range)                              132 (19--2065)
  Intolerant to imatinib, *n* (%)[c](#t1-fn4){ref-type="fn"}         8 (21.1)
  Gene mutation                                                       
   *KIT* mutation                                                     
    Exon 9                                                           5 (13.2)
    Exon 11                                                          14 (36.8)
    Exon 17                                                          1 (2.6)
    Exons 11 and 17                                                  1 (2.6)
   *PDGFRA* mutation                                                  
    Exon 12                                                          1 (2.6)
    Exon 18                                                          1 (2.6)
    Exon D842V                                                       2 (5.3)
  Not available                                                      13 (34.2)

Abbreviations: ECOG=Eastern Cooperative Oncology Group; HPF=high power fields.

Patients for whom the mitotic index was not recorded as fraction of 50 HPFs.

One patient may have more than one metastatic site.

Three patients reported as both progressed on imatinib and intolerant to imatinib.

###### The best overall response (rederived and by investigator assessment) as per RECIST at week 12 on study and at the end of treatment

  **Time-point variable**                             ***N*****=38** ***n*** **(%)**    **90% confidence interval**[a](#t2-fn3){ref-type="fn"}
  --------------------------------------------------- -------------------------------- --------------------------------------------------------
  **Week 12 (rederived)**                                                              
  CR                                                  0                                                            
  PR                                                  1 (2.6)                                                      
  SD                                                  19 (50.0)                                                    
  PD                                                  5 (13.2)                                                     
  Unknown                                             13 (34.2)                                                    
  ORR (CR or PR)                                      1 (2.6)                                                (0.1--11.9)
  DCR (CR or PR or SD)                                20 (52.6)                                              (38.2--66.7)
  **Week 12 (by investigator assessment)**                                             
  CR                                                  0                                                            
  PR                                                  1 (2.6)                                                      
  SD                                                  20 (52.6)                                                    
  PD                                                  5 (13.2)                                                     
  Unknown                                             12 (31.6)                                                    
  ORR (CR or PR)                                      1 (2.6)                                                (0.1--11.9)
  DCR (CR or PR or SD)                                21 (55.3)                                              (40.7--69.1)
  **End of treatment (rederived)**                                                     
  CR                                                  0                                                            
  PR                                                  2 (5.3)                                                      
  SD                                                  18 (47.4)                                                    
  PD                                                  5 (13.2)                                                     
  Unknown                                             13 (34.2)                                                    
  ORR (CR or PR)                                      2 (5.3)                                                (0.9--15.7)
  DCR (CR or PR or SD)                                20 (52.6)                                              (38.2--66.7)
  **End of treatment (by investigator assessment)**                                    
  CR                                                  0                                                            
  PR                                                  2 (5.3)                                                      
  SD                                                  21 (55.3)                                                    
  PD                                                  5 (13.2)                                                     
  Unknown                                             10 (26.3)                                                    
  ORR (CR or PR)                                      2 (5.3)                                                (0.9--15.7)
  DCR (CR or PR or SD)                                23 (60.5)                                              (45.9--73.9)

Abbreviations: CR=complete response; DCR=disease control rate; ORR=overall response rate; PD=progressive disease; PR=partial response; SD=stable disease.

The recalculated best overall response is presented together with the investigator assessment. Assessments taken more than 28 days after last dose of study treatment are excluded from derivation of best overall response.

Exact binomial confidence interval.

###### The most frequently recorded adverse events (occurred in \>30% of the patients)

                                         **Dovitinib (*****N*****=39)**                           
  -------------------------------------- -------------------------------- ----------- ----------- ----------
  Patients with any AE                   2 (5.1)                          10 (25.6)   17 (43.6)    8 (20.5)
  Adverse effect                                                                                       
   Diarrhoea                             14 (35.9)                        11 (28.2)   3 (7.7)         0
   Vomiting                              10 (25.6)                        7 (17.9)    4 (10.3)        0
   Nausea                                6 (15.4)                         9 (23.1)    2 (5.1)         0
   Asthenia                              5 (12.8)                         8 (20.5)    1 (2.6)      1 (2.6)
   Decreased appetite                    6 (15.4)                         7 (17.9)    2 (5.1)         0
   Fatigue                               3 (7.7)                          6 (15.4)    5 (12.8)        0
   *γ*-Glutamyl transferase increase     4 (10.3)                         5 (12.8)    4 (10.3)     1 (2.6)
   Blood alkaline phosphatase increase   9 (23.1)                         2 (5.1)     2 (5.1)         0
   Hypertension                          0                                6 (15.4)    7 (17.9)        0
   Hypertriglyceridaemia                 2 (5.1)                          7 (17.9)    4 (10.3)        0
   Weight decreased                      8 (20.5)                         3 (7.7)     1 (2.6)         0

Abbreviation: AE=adverse events.

Only adverse effects that occurred during dovitinib treatment or within 28 days from the last day of dovitinib administration are reported.
